https://doi.org/10.4081/monaldi.2013.32

Roflumilast is effective in reducing COPD related exacerbations and improving CAT score

Vol. 79 No. 3-4 (2013): Pulmonary series - Supplement 1
Submitted: August 19, 2015
Accepted: August 19, 2015
Published: August 19, 2015
Roflumilast, COPD, Case report, Exacerbations, Steroid therapy
Abstract Views: 746
PDF: 593
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Biagio Polla
bpolla@ospedale.al.it
Respiratory Physiopathology and Anti-Smoke Center, “SS. Antonio e Biagio e Cesare Arrigo” Hospital, Alessandria, Italy.
We present a case of a 85-year-old man who suffered from several chronic obstructive pulmonary disease (COPD) related exacerbations and hospitalizations. Traditional therapy, which also included intramuscular steroid therapy, did not help and caused several drug related adverse events. After yet another exacerbation followed by hospitalization at the intensive care unit, it was decided to start roflumilast treatment. In the year after beginning treatment, the patient did not experience any more exacerbations and his lung function also improved, as recorded by the COPD assessment test (CAT) score and improved forced expiratory volume in the first second (FEV1) value. In this patient roflumilast seems to be effective in reducing exacerbations, an important goal to be achieved in COPD patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Polla, Biagio. 2015. “Roflumilast Is Effective in Reducing COPD Related Exacerbations and Improving CAT Score”. Monaldi Archives for Chest Disease 79 (3-4). https://doi.org/10.4081/monaldi.2013.32.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.